Plain-English translation of NCT07274059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new approach called allogeneic umbilical cord blood-derived CAR T-cell therapy (UCAR-T cells) for people with lupus that hasn't improved with conventional treatments. Researchers will infuse specially engineered immune cells into participants' bodies to see if the treatment can reduce lupus activity and help patients go into remission. The trial will monitor participants closely for safety and effectiveness over two years.
Lupus is a serious autoimmune disease that doesn't respond well to standard medications for about 30-40% of patients. This trial explores whether this new cell-based therapy could offer hope to people with hard-to-treat lupus who have limited options.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for screening tests to confirm you qualify. If enrolled, you may receive two days of preparatory chemotherapy (to help the new cells take hold), followed by a single infusion of the engineered immune cells. You'll stay in the hospital for at least 7 days afterward for close monitoring, and you must stay within 2 hours of the treatment facility for at least 28 days. You'll then return for check-ups at 2 weeks, 4 weeks, 3 months, 6 months, 9 months, 1 year, 18 months, and 2 years to track how you're responding.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China